Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

Abstract The investigational NEDD8‐activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine versus single‐agent azacitidine in patients with higher‐risk myelodysplastic syndrome (higher‐risk MDS), higher‐risk chronic myelomonocytic leukemia (higher‐risk CMML), or l...

Full description

Bibliographic Details
Main Authors: Xiaofei Zhou, Sharon Friedlander, Erik Kupperman, Farhad Sedarati, Shingo Kuroda, Zhaowei Hua, Ying Yuan, Yuka Yamamoto, Douglas V. Faller, Kazue Haikawa, Katsuhiko Nakai, Sharon Bowen, Yi Dai, Karthik Venkatakrishnan
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12972

Internet

https://doi.org/10.1111/cts.12972

Similar Items